Most Read Articles
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab

Aspirin may increase rate of haemorrhagic events in elderly hypertensive patients

07 Jun 2019
For nearly 100 years, aspirin has been a common drug used for pain relief and fever treatment.

Low-dose aspirin therapy does not confer significant benefits to elderly patients with hypertension, but treatment appears to increase the risk of haemorrhagic events, suggest a Japan study.

Aspirin therapy in hypertensive patients did not improve the primary outcome of death from cardiovascular disease, nonfatal stroke and nonfatal myocardial infarction, but it was significantly associated with higher incidence of serious extracranial haemorrhage (hazard ratio [HR], 1.81, 95 percent CI, 1.18–2.77; p=0.0064) and haemorrhagic stroke (HR, 1.75, 0.99–3.07; p=0.053).

Furthermore, aspirin did not significantly influence the primary outcome in any of the blood pressure (BP) subgroups. Aspirin even increased the incidence of haemorrhagic stroke in the high BP group (HR, 3.51, 1.29–9.51; p=0.014). Moreover, there was an increase, or a tendency to increase, in extracranial haemorrhage in the moderate (HR, 2.53, 1.18–5.45; p=0.017) and high (HR, 2.14, 1.00–4.56; p=0.050) BP groups.

The investigators used data from patients aged 60–85 years with hypertension, dyslipidaemia and/or diabetes, but without cardiovascular disease, of the Japanese Primary Prevention Project to examine whether BP influenced the efficacy of low-dose acetylsalicylic acid for the primary prevention of cardiovascular events.

A total of 12,278 patients were assigned to aspirin (100 mg/day) or no aspirin and were further categorized into BP subgroups: low (average systolic BP form the baseline to the year of the events, <130 mm Hg), moderate (130 and <140 mm Hg) and high (≥140 mm Hg). Mean duration of follow-up was 5.02 years.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab